Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.

@article{Wu2010SecondlineTA,
  title={Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.},
  author={Jenn-Yu Wu and Jin-Yuan Shih and C J Yang and Kuan-Yu Chen and Chao-Chi Ho and Chong-Jen Yu and Pan-Chyr Yang},
  journal={International journal of cancer},
  year={2010},
  volume={126 1},
  pages={247-55}
}
Gefitinib is effective as first-line therapy for advanced nonsmall cell lung cancer (NSCLC). However, after failure of gefitinib, it is unknown whether any second-line regimens could lead to better outcomes. To study the influence of different second-line antitumor regimens on the outcomes of patients with NSCLC after failure of first-line gefitinib, we carried out a retrospective study in a tertiary referral medical center to investigate the prognosis of patients with NSCLC receiving second… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico • 2015
View 1 Excerpt

Similar Papers

Loading similar papers…